Khorana score to predict thrombosis in outpatients initiating chemotherapy
| Patient characteristic . | Points . |
|---|---|
| Site of cancer | |
| Very high risk (stomach, pancreas) | 2 |
| High risk (lung, lymphoma, gynecologic, genitourinary excluding prostate) | 1 |
| Prechemotherapy platelet count ≥350 × 109/L | 1 |
| Hemoglobin ≤100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count ≥11 × 109/L | 1 |
| Body mass index ≥35 kg/m2 | 1 |
| Patient characteristic . | Points . |
|---|---|
| Site of cancer | |
| Very high risk (stomach, pancreas) | 2 |
| High risk (lung, lymphoma, gynecologic, genitourinary excluding prostate) | 1 |
| Prechemotherapy platelet count ≥350 × 109/L | 1 |
| Hemoglobin ≤100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count ≥11 × 109/L | 1 |
| Body mass index ≥35 kg/m2 | 1 |
Risk category and rate of thrombosis: low (0 points), 0.3% to 0.8%; intermediate (1-2 points), 1.8% to 2%; high (≥3 points), 6.7% to 7.1%. See Khorana et al.58